$1.52
2.01%
Nasdaq, Sep 29, 04:00 pm EDT. Closed.
ISIN
US74638P1093
Symbol
PPBT

Purple Biotech Ltd - ADR Stock price

$1.52
-0.18 10.59% 1M
-2.21 59.19% 6M
-5.06 76.88% YTD
-4.38 74.22% 1Y
-236.48 99.36% 3Y
-902.48 99.83% 5Y
-6,998.48 99.98% 10Y
-6,378.48 99.98% 20Y
Nasdaq, Closing price Tue, Sep 29 2026
+0.03 2.01%
ISIN
US74638P1093
Symbol
PPBT
Industry

Is Purple Biotech Ltd - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,127 stocks worldwide.

Key metrics

Basic
Market capitalization
$10.6m
Enterprise Value
$4.6m
Net debt
positive
Cash
$6.1m
Shares outstanding
1.9b
Valuation (TTM | estimate)
P/E
negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
0.9
Financial Health
Equity Ratio
55.3%
Return on Equity
-271.6%
ROCE
-228.9%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-28.1m
EBIT
$-28.4m
Net Income
$-24.5m
Free Cash Flow
$-7.8m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-400.2%
EBIT
-389.1%
Net Income
-838.3%
Free Cash Flow
12.0%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow
-
More
EPS
$0.0
FCF per Share
$0.0
Short interest
5.0%
Employees
-
Rev per Employee
-

Financial data from Purple Biotech Ltd - ADR

Jun '26
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 3.53 3.53
32% 32%
-
- Research and Development Expense 4.35 4.35
39% 39%
-
-28 -28
400% 400%
-
- Depreciation and Amortization 0.25 0.25
39% 39%
-
EBIT (Operating Income) EBIT -28 -28
389% 389%
-
Net Profit -24 -24
838% 838%
-

In millions USD.

Don't miss a Thing! We will send you all news about Purple Biotech Ltd - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Purple Biotech Ltd - ADR Stock News

Neutral
GlobeNewsWire
●
28 days ago
REHOVOT, Israel, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or the “Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing a next-generation immunotherapy platform designed to maximize anti-cancer activity while minimizing toxicity, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent applicatio...

Company Profile

Purple Biotech Ltd. is a development stage pharmaceutical company, which engages in drug development. It operates through two segments: Oncology, and Pain & Hypertension. The Oncology segment includes NT219, a therapeutic candidate which is a small molecule that targets two signal transduction pathways which are involved in the development of cancer drug resistance mechanisms, and which is currently in the late pre-clinical stage of development. The Pain & Hypertension segment includes Consensi, a combination drug for the simultaneous treatment of two clinical conditions, pain caused by osteoarthritis and hypertension (high blood pressure), which can be pre-existing or caused by the treatment for osteoarthritis. The company was founded by John Paul Waymack on August 12, 1968 and is headquartered in Tel Aviv, Israel.

Head office Israel
CEO Mr. Israel
Founded 1968
Website purple-biotech.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today